HCFA's Hands-Off Policy For Ocular Laser Therapy Leaves Control At Bedside
This article was originally published in The Gray Sheet
Executive Summary
HCFA's Nov. 8 decision on photodynamic laser treatments for age-related macular degeneration (AMD) demonstrates a new willingness to defer to physician judgement in the selection of appropriate patients.
You may also be interested in...
Novartis, QLT Will Expand Visudyne Population Following Approvable Letter
Novartis Ophthalmics' submission to FDA of interim data analyses from a Phase II study evaluating its Visudyne photodynamic therapy to treat ocular histoplasmosis syndrome (OHS) is likely to secure approval of its supplemental new drug application.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.